Champions Oncology Inc (NASDAQ:CSBR) Sees Significant Increase in Short Interest

Champions Oncology Inc (NASDAQ:CSBR) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 187,200 shares, an increase of 14.9% from the September 30th total of 162,900 shares. Based on an average daily trading volume, of 32,300 shares, the days-to-cover ratio is currently 5.8 days. Approximately 3.2% of the shares of the company are short sold.

Several hedge funds and other institutional investors have recently made changes to their positions in CSBR. Marshall Wace LLP acquired a new stake in shares of Champions Oncology in the first quarter valued at about $99,000. Wedge Capital Management L L P NC acquired a new position in Champions Oncology during the second quarter worth about $277,000. Wells Fargo & Company MN boosted its position in Champions Oncology by 110.4% during the second quarter. Wells Fargo & Company MN now owns 149,100 shares of the biotechnology company’s stock worth $1,167,000 after acquiring an additional 78,250 shares during the last quarter. Alambic Investment Management L.P. boosted its position in Champions Oncology by 27.0% during the second quarter. Alambic Investment Management L.P. now owns 68,681 shares of the biotechnology company’s stock worth $538,000 after acquiring an additional 14,614 shares during the last quarter. Finally, BlackRock Inc. boosted its position in Champions Oncology by 12.0% during the second quarter. BlackRock Inc. now owns 137,027 shares of the biotechnology company’s stock worth $1,073,000 after acquiring an additional 14,733 shares during the last quarter. Institutional investors and hedge funds own 50.92% of the company’s stock.

Several analysts recently commented on the stock. Janney Montgomery Scott lowered shares of Champions Oncology from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 24th. Roth Capital started coverage on shares of Champions Oncology in a research report on Friday, September 20th. They issued a “buy” rating and a $9.25 target price on the stock. ValuEngine upgraded shares of Champions Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Finally, Zacks Investment Research upgraded shares of Champions Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, September 24th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $13.13.

Shares of NASDAQ CSBR opened at $5.59 on Wednesday. The company’s 50-day simple moving average is $5.68 and its 200-day simple moving average is $7.11. Champions Oncology has a 52-week low of $5.01 and a 52-week high of $13.57. The firm has a market cap of $61.12 million, a price-to-earnings ratio of 559.00 and a beta of 1.15. The company has a quick ratio of 0.80, a current ratio of 0.80 and a debt-to-equity ratio of 2.06.

Champions Oncology (NASDAQ:CSBR) last announced its earnings results on Monday, September 16th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.03 by ($0.09). Champions Oncology had a negative net margin of 3.61% and a negative return on equity of 48.07%. The company had revenue of $6.74 million during the quarter, compared to analyst estimates of $7.50 million. Equities research analysts anticipate that Champions Oncology will post 0.01 EPS for the current fiscal year.

About Champions Oncology

Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

Recommended Story: Google Finance

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.